Design, synthesis, docking, ADMET and anticancer evaluations of
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
08 Dec 2023
08 Dec 2023
Historique:
received:
10
11
2023
accepted:
01
12
2023
medline:
14
12
2023
pubmed:
14
12
2023
entrez:
14
12
2023
Statut:
epublish
Résumé
Fifteen new 1-alkyl-6-iodoquinazoline derivatives 5a-d to 9a-e were designed and synthesized and their anticancer activities were evaluated against HepG2, MCF-7, HCT116 and A549 cancer cell lines
Identifiants
pubmed: 38093733
doi: 10.1039/d3ra07700d
pii: d3ra07700d
pmc: PMC10716637
doi:
Types de publication
Journal Article
Langues
eng
Pagination
36301-36321Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.